Speaker(s): 

Michael A. Sulzinski, PhD, Faculty Member, Geisinger Commonwealth School of Medicine- has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the historical understanding of hepatitis C virus (HCV) from non-A non-B hepatitis to the discovery of HCV in 1989.
• Summarize the biological and molecular properties of HCV, including genotypes.
• Illustrate the clinical manifestations of HCV infection and possible sequelae, including hepatocellular carcinoma.
• Explain how HCV is transmitted, and list population groups most at risk for HCV infection and describe the global burden of HCV infection.
• Explain how molecular testing is applied to design anti-viral drug therapies that accomplish sustained virological responses (cures).
• Predict challenges faced in the development of an HCV vaccine that is safe and efficacious.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Anne Gallagher, MHSA - Activity Director, Rebecca Slangan, MBA - Activity Director, Kelly Shaw, PsyD, Jackie Ghormoz, MSW, CSW, Daniel Longyhore, PharmD, EdD, Samantha Kunkel, PharmD, Mary Lawhon Triano, MSN, CRNP-C, Christopher DeFrancesco, PharmD, Shubhra Shetty, MD and Rahul Joshi, Medical Student have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commerical Support for this Session